Golidocitinib is a selective Janus kinase (JAK) inhibitor and a small-molecule tyrosine kinase inhibitor used primarily for the treatment of moderate-to-severe atopic dermatitis in adults. By blocking… Read more
Golidocitinib is a selective Janus kinase (JAK) inhibitor and a small-molecule tyrosine kinase inhibitor used primarily for the treatment of moderate-to-severe atopic dermatitis in adults. By blocking the JAK-STAT signaling pathway, it helps manage the inflammation and pruritus associated with this autoimmune skin condition. The range of associated golidocitinib reference standards, including pharmaceutical impurities, metabolites, and stable isotope labelled compounds, is critical for analytical chemists and researchers in the pharmaceutical industry. These high-quality compounds are essential for impurity profiling, method validation, and the development of accurate analytical techniques like high-performance liquid chromatography (HPLC). Laboratories rely on these materials to quantify parent drug levels precisely within complex biological matrices during rigorous pharmacokinetic studies, bioanalysis, and routine quality control assays to ensure drug safety and efficacy.